J7608Acetylcysteine non-comp unit
Published CMS Medicare Part B payment-limit context for J7608, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$7.274
per 1 GM · Medicare Part B
Down 14.8%from $8.541 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$9.1185$7.0475
2024-Q4: $7.772; 2025-Q1: $8.147; 2025-Q2: $8.437; 2025-Q3: $8.892; 2025-Q4: $8.655; 2026-Q1: $8.455; 2026-Q2: $8.541; 2026-Q3: $7.274
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Acetylcysteine ingredient family (FDA data as of August 20, 2026).
Acetylcysteine
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Acetylcysteine presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J0132 | Acetylcysteine injection | $0.389 per 100 MG | $0.511 per 100 MG | Down 23.9% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.